reports
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
- ABGSC Construct. & Real Estate Research
- Åsne Holsen
- Bengt Jonassen
Aktietilbagekøb: Transaktioner i uge 20 2025
Aktietilbagekøb: Transaktioner i uge 20 2025 Aktietilbagekøbsprogrammet løber i perioden fra og med den 26. februar 2025 til senest den 30. januar 2026. I denne periode vil Jyske Bank erhverve egne aktier til en maksimal værdi af 2,25 mia. kroner i et aktietilbagekøbsprogram, jf. selskabsmeddelelse nr. 3/2025 af 26. februar 2025. Aktietilbagekøbsprogrammet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014, også kaldet ”Markedsmisbrugsforordningen”, og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016 (tilsammen ”safe habour-regler”). ...
Share repurchase programme: Transactions of week 20 2025
Share repurchase programme: Transactions of week 20 2025 The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Ab...
Ambu AS: 1 director
A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Aktietilbagekøb: Transaktioner i uge 19 2025
Aktietilbagekøb: Transaktioner i uge 19 2025 Aktietilbagekøbsprogrammet løber i perioden fra og med den 26. februar 2025 til senest den 30. januar 2026. I denne periode vil Jyske Bank erhverve egne aktier til en maksimal værdi af 2,25 mia. kroner i et aktietilbagekøbsprogram, jf. selskabsmeddelelse nr. 3/2025 af 26. februar 2025. Aktietilbagekøbsprogrammet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014, også kaldet ”Markedsmisbrugsforordningen”, og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016 (tilsammen ”safe habour-regler”). ...
Share repurchase programme: Transactions of week 19 2025
Share repurchase programme: Transactions of week 19 2025 The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Ab...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
Coloplast AS: 1 director
A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Geir Hiller Holom
PhotoCure (Buy, TP: NOK80.00) - Generally in line
Photocure reported c7% YOY product revenue growth for Q1, but operating expenses rose substantially, resulting in EBIT of NOK-5.6m, down YOY from NOK0.7m in Q1 2024. The company reiterated its guidance for 2025. A webcast is scheduled for today at 14:00 CET.
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
- ABGSC Healthcare Research
- Morten Larsen
- Jesper Ingildsen
Ambu (Buy, TP: DKK144.00) - Possibly isolated softness
Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).
- ABGSC Consumer Goods Research
- Benjamin Wahlstedt
- Mikkel Kousgaard Rasmussen
Delårsrapport 1. kvartal 2025
Delårsrapport 1. kvartal 2025 Resultat pr. aktie 19,4 kr. (1. kvt. 2024: 19,0 kr.)Basisindtægter 3.229 mio. kr. (1. kvt. 2024: 3.430 mio. kr.)Basisomkostninger 1.533 mio. kr. (1. kvt. 2024: 1.557 mio. kr.)Nedskrivninger på udlån mv. 66 mio. kr. (1. kvt. 2024: 82 mio. kr.)Ledelsesmæssigt skøn vedrørende nedskrivninger forøget til 1.869 mio. kr. (ultimo 2024: 1.782 mio. kr.)Kapitalprocent på 20,9, heraf egentlig kernekapitalprocent på 15,7 (1. kvt. 2024: hhv. 22,0 og 16,6) Sammendrag ” Jyske Bank har haft en god start på året med fortsat fremgang. Samtidigt har vi løftet kundetilfredsheden ...
Interim Financial Report, Q1 2025
Interim Financial Report, Q1 2025 Earnings per share DKK 19.4 (Q1 2024: DKK 19.0)Core income DKK 3,229m (Q1 2024: DKK 3,430m)Core expenses DKK 1,533m (Q1 2024: DKK 1,557m)Loan impairment charges: DKK 66m (Q1 2024: DKK 82m)Post-model adjustments relating to loan impairment charges was up to DKK 1,869m (end of 2024: DKK 1,782m).Capital ratio at 20.9%, of which common equity tier 1 capital ratio of 15.7% (Q1 2024: 22.0% and 16.6%, respectively) Summary ”Jyske Bank has got off to a good start to the year with continued progress. In addition, we have boosted customer satisfaction, among person...
- ABGSC Healthcare Research
- Morten Larsen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.